The FINANCIAL — Sanofi announced on January 4 that Soliqua 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) is now available by prescription in U.S. pharmacies. Soliqua ...

Soliqua 100/33 will be delivered in a single pre-filled pen for once-daily dosing covering 15 to 60 Units of insulin glargine 100 Units/mL and 5 to 20 mcg of lixisenatide using SoloStar technology, ...

The once-daily injection (Soliqua), a fixed combination of 100 U/mL insulin glargine (Lantus) and 33 µg/mL of the GLP-1 receptor agonist lixisenatide (Adlyxin), was previously approved for use as ...

Paris, France - January 4, 2017 - Sanofi announced today that Soliqua (TM) 100/33 (insulin glargine 100 Units/mL & lixisenatide * 33 mcg/mL injection) is now available by prescription in U.S ...

Copenhagen, 4 January 2017 - Zealand Pharma (Zealand) reports that Sanofi announced today that Soliqua (TM) 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) is now available ...